First 10 Patients Data In Q1 2018, Build Up end of Q4 2017Short term highlights are: All clinical supplies already available for first 10 patients.
4th clinical site to be opened for speeding up recruitment.
Frozen formulation of BriaVax for easy transportation.
Immunoassays to measure response to BriaVax.
Cloned BriaVax for more powerful GM-CSF.
Combination of BriaVax and immune simulator from U of Zurich.
Patent application for the U of Zurich combo/simulator Q4 2017.
PKC Inhibitors activity against RAS transformed cancers.
Briacell is progressing it's Phase I/IIa study on schedule with successful data of the first 10 patients to be released Q1 2018.
Also it is impressive to note a "conservative estimate" for the total market potential of PKC Inhibitors is $2 Billion/year.
We're expecting Briavax and the team of high powered Dr's to garner serious attention end of Q4 2017. Look for a share price increase, build up and catalyst before Q1 2018 in anticipation of the data on the first 10 patients. Of course we all know of the huge insider ownership and commitment from the CEO Dr. Williams. Don't miss out on an amazing share price trading way undervalue. You wont find a harder working team than this. Jmo.